- Home
- CGEN vs COYA Comparison
CGEN vs COYA Comparison
Compare CGEN & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- COYA
- Stock Information
- Founded
- CGEN 1993
- COYA 2020
- Country
- CGEN Israel
- COYA United States
- Employees
- CGEN N/A
- COYA N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- CGEN Health Care
- COYA Health Care
- Exchange
- CGEN Nasdaq
- COYA Nasdaq
- Market Cap
- CGEN 125.3M
- COYA 107.0M
- IPO Year
- CGEN 2000
- COYA 2022
- Fundamental
- Price
- CGEN $1.95
- COYA $6.30
- Analyst Decision
- CGEN
- COYA Strong Buy
- Analyst Count
- CGEN 0
- COYA 5
- Target Price
- CGEN N/A
- COYA $16.20
- AVG Volume (30 Days)
- CGEN 560.3K
- COYA 127.3K
- Earning Date
- CGEN 11-11-2025
- COYA 11-05-2025
- Dividend Yield
- CGEN N/A
- COYA N/A
- EPS Growth
- CGEN N/A
- COYA N/A
- EPS
- CGEN N/A
- COYA N/A
- Revenue
- CGEN $22,144,000.00
- COYA $423,452.00
- Revenue This Year
- CGEN N/A
- COYA $40.80
- Revenue Next Year
- CGEN $208.08
- COYA N/A
- P/E Ratio
- CGEN N/A
- COYA N/A
- Revenue Growth
- CGEN N/A
- COYA N/A
- 52 Week Low
- CGEN $1.13
- COYA $4.65
- 52 Week High
- CGEN $2.66
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- CGEN 60.17
- COYA 52.12
- Support Level
- CGEN $1.30
- COYA $5.83
- Resistance Level
- CGEN $2.38
- COYA $7.75
- Average True Range (ATR)
- CGEN 0.17
- COYA 0.47
- MACD
- CGEN 0.04
- COYA 0.08
- Stochastic Oscillator
- CGEN 57.00
- COYA 35.84
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.